Search research articles
Contact Us
Filters
Showing results (41-50 of 231) with videos related to
Page
of 24
Sort By:
Blood Cancer Journal
|
March 27, 2025
Correction: The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
Pralay Mukhopadhyay, Hesham A Abdullah, Joanna B Opalinska, et al.
European Journal of Haematology
|
November 16, 2023
Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study
Fredrik H Schjesvold, Heinz Ludwig, Maria-Victoria Mateos, et al.
The Lancet. Oncology
|
June 6, 2018
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study
Philippe Moreau, Maria-Victoria Mateos, James R Berenson, et al.
Leukemia & Lymphoma
|
February 2, 2012
Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience
Adrian Alegre, Albert Oriol-Rocafiguera, Jose Garcia-Larana, et al.
Lancet (London, England)
|
July 20, 2020
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
Meletios Dimopoulos, Hang Quach, Maria-Victoria Mateos, et al.
Leukemia & Lymphoma
|
November 6, 2019
The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison
Maria-Victoria Mateos, Jesus San-Miguel, Hartmut Goldschmidt, et al.
Blood Advances
|
September 30, 2024
Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis
Mohammad S Ebraheem, Rajshekhar Chakraborty, Bram Rochwerg, et al.
Haematologica
|
April 19, 2012
Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?
Sergio Matarraz, Bruno Paiva, María Diez-Campelo, et al.
Leukemia & Lymphoma
|
November 6, 2019
A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomide (MPT)
Meletios A Dimopoulos, Michele Cavo, Maria-Victoria Mateos, et al.
Future Oncology (London, England)
|
April 27, 2026
Plain language summary of a study on 30-minute intravenous infusion of isatuximab in people with newly diagnosed multiple myeloma
Enrique M Ocio, Aurore Perrot, Philippe Moreau, et al.
Page
of 24
Search research articles
Search
Showing results (41-50 of 231) with videos related to
Sort By:
Page
of 24
Blood Cancer Journal
|
March 27, 2025
Correction: The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
Pralay Mukhopadhyay, Hesham A Abdullah, Joanna B Opalinska, et al.
European Journal of Haematology
|
November 16, 2023
Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study
Fredrik H Schjesvold, Heinz Ludwig, Maria-Victoria Mateos, et al.
The Lancet. Oncology
|
June 6, 2018
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study
Philippe Moreau, Maria-Victoria Mateos, James R Berenson, et al.
Leukemia & Lymphoma
|
February 2, 2012
Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience
Adrian Alegre, Albert Oriol-Rocafiguera, Jose Garcia-Larana, et al.
Lancet (London, England)
|
July 20, 2020
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
Meletios Dimopoulos, Hang Quach, Maria-Victoria Mateos, et al.
Leukemia & Lymphoma
|
November 6, 2019
The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison
Maria-Victoria Mateos, Jesus San-Miguel, Hartmut Goldschmidt, et al.
Blood Advances
|
September 30, 2024
Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis
Mohammad S Ebraheem, Rajshekhar Chakraborty, Bram Rochwerg, et al.
Haematologica
|
April 19, 2012
Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?
Sergio Matarraz, Bruno Paiva, María Diez-Campelo, et al.
Leukemia & Lymphoma
|
November 6, 2019
A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomide (MPT)
Meletios A Dimopoulos, Michele Cavo, Maria-Victoria Mateos, et al.
Future Oncology (London, England)
|
April 27, 2026
Plain language summary of a study on 30-minute intravenous infusion of isatuximab in people with newly diagnosed multiple myeloma
Enrique M Ocio, Aurore Perrot, Philippe Moreau, et al.
Page
of 24